Emerging from the UK, retatrutide, a novel compound , is generating considerable excitement within the healthcare community regarding its promise for physique regulation. This dual GIP and GLP-1 agent agonist seems to deliver a significant improvement over current therapies, showing positive results in initial clinical studies . Researchers suggest